Levamlodipine/telmisartan - Chong Kun Dang

Drug Profile

Levamlodipine/telmisartan - Chong Kun Dang

Alternative Names: CKD-345; CKD-828; CKD-828(FDC); S-amlodipine/telmisartan; Telminuvo Tab; Telmisartan/S-amlodipine; Telmunivo

Latest Information Update: 09 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Chong Kun Dang
  • Class Antihypertensives; Benzimidazoles; Benzoates; Dihydropyridines; Nicotinic-acids; Small molecules
  • Mechanism of Action ACE inhibitors; Angiotensin type 1 receptor antagonists; Calcium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hypertension

Most Recent Events

  • 31 Aug 2018 Chong Kun Dang Pharmaceutical initiates enrolment in a phase I trial for Hypertension (In volunteers) in South Korea (NCT03726866)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Hypertension(Combination therapy, In volunteers) in South Korea (PO, Tablet)
  • 01 Jun 2015 Chong Kun Dang Pharmaceutical completes a phase I pharmacokinetics study in Healthy volunteers in South Korea (NCT02358824)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top